Pyramid Biosciences, Inc

Genentech, Inc.

F. Hoffmann-la Roche Ag

Biohaven Therapeutics Ltd.

Jonathan Boudreault

Stephane Ciblat

Kollol Pal

Nicolas Bruneau-Latour

Vincent Albert

Claudio F Sturino

Michael F T Koehler

Peter Andrew Smith

Dana Winter

Boubacar Sow

Guillaume Pelletier

Claudio Sturino

Michael Friedrich Thomas Koehler

The application relates to pyrazolo[1,5-a]pyrimidine derivatives of formula (IV) as Trk kinase inhibitors for treating cancer and inflammatory diseases.

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

The application relates to inhibitors of Trk kinases useful in the treatment of Trk kinase associated diseases and disorders, having the Formula: wherein A, L, X, X, and Y are described herein.

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Macrocyclic broad spectrum antibiotics

Growing community of inventors

L'Ile-Perrot, Canada

Jonathan Boudreault